News for 'Sun Pharmaceuticals'

You can have a career in medicine without giving NEET

You can have a career in medicine without giving NEET

Rediff.com8 Dec 2023

rediffGURU Mayank Chandel offers advice to students interested in a careers in science or engineering after class 10 and 12.

India Inc capital expenditure story gets cement to semiconductor push

India Inc capital expenditure story gets cement to semiconductor push

Rediff.com19 Apr 2024

Corporate India is starting to step up its capital expenditure plans amid government incentives and signs of rising demand, company executives and analysts have indicated. This coincides with the Reserve Bank of India (RBI) recently citing a double-digit growth in private capital expenditure. Healthy balance sheets of banks and corporates, along with increasing capacity utilisation and improving business sentiment, are contributing to a favourable environment for sustained growth in private sector investments, the RBI said in its policy last week.

India-EFTA trade pact: How Swiss firms stand to gain

India-EFTA trade pact: How Swiss firms stand to gain

Rediff.com10 Mar 2024

Domestic customers will get access to high-quality Swiss products such as watches, chocolates, biscuits, and clocks at lower prices as India will phase out customs duties under its trade pact with the EFTA bloc on these goods over a period of time. India and the four-European nation bloc EFTA signed a trade and economic partnership agreement (TEPA) on Sunday to boost trade and investments between the two regions. The European Free Trade Association (EFTA) members are Iceland, Liechtenstein, Norway, and Switzerland.

India, EFTA sign $100-billion free trade pact

India, EFTA sign $100-billion free trade pact

Rediff.com10 Mar 2024

Domestic customers will get access to high-quality Swiss products such as watches, chocolates, biscuits, and clocks at lower prices as India will phase out customs duties under its trade pact with the EFTA bloc on these goods over a period of time. India and the four-European nation bloc EFTA signed a trade and economic partnership agreement (TEPA) on Sunday to boost trade and investments between the two regions. The European Free Trade Association (EFTA) members are Iceland, Liechtenstein, Norway, and Switzerland.

Ram Teri Ganga Maili

Ram Teri Ganga Maili

Rediff.com12 Jun 2024

Six decades and more later, we are now captives of our identities. Every poll is based on elaborate calculations of electability of candidates on the basis of their castes and other narrow definers. That, along with voter promiscuity, is what defines our political culture, which remains stubbornly resistant to any change, asserts Shreekant Sambrani.

Are Indian Markets Overstretched?

Are Indian Markets Overstretched?

Rediff.com27 Feb 2024

The index is currently trading at 149 per cent of its historical P/B valuation, surpassing its previous peak of 125 per cent made in 2020-21.

Uzbek cough syrup deaths: Govt to scrap Marion Biotech's licence

Uzbek cough syrup deaths: Govt to scrap Marion Biotech's licence

Rediff.com5 Mar 2023

The two directors of the company named in the FIR, however, still remain at large.

'Prefer largecap to midcaps and smallcaps'

'Prefer largecap to midcaps and smallcaps'

Rediff.com31 Oct 2023

'Midcap and smallcap indices are trading in the expensive zone.'

What's in store for mutual fund investors in 2024?

What's in store for mutual fund investors in 2024?

Rediff.com30 Jan 2024

The mutual fund (MF) industry had an action-packed 2023 as it tackled the scrapping of tax benefits for debt fund investors and surging flows into equity funds.

BFSI weighting in Nifty50 hits 7-year low as HDFC slips

BFSI weighting in Nifty50 hits 7-year low as HDFC slips

Rediff.com29 Jan 2024

After a sharp fall in the share prices of HDFC Bank and other private sector lenders in the past three days, the BFSI (banking, financial services and insurance) sector weighting in the Nifty50 has slipped to a seven-year low of 32.03 per cent, down from nearly 36.6 per cent at the end of March 2023 and 34.5 per cent at the end of December 2023.

Budget 2023: What the pharma, healthcare industry seek

Budget 2023: What the pharma, healthcare industry seek

Rediff.com19 Jan 2023

The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Outlining the wish list for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said the domestic pharma industry is currently around $50 billion in size and aspires to grow to around $130 billion by 2030 and $450 billion by 2047. "To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward," he told PTI.

Sun Pharma recalls over 34k bottles of generic drug in US

Sun Pharma recalls over 34k bottles of generic drug in US

Rediff.com11 Feb 2023

Drug major Sun Pharma is recalling over 34,000 bottles of a generic medication, used to treat high blood pressure, in the US market due to failed dissolution testing. As per the US Food and Drug Administration's Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling lots of Diltiazem Hydrochloride extended-release capsules which are used to treat angina, high blood pressure and some types of irregular heartbeats.

Drug sales stuck at pre-pandemic level, price rise shapes market growth

Drug sales stuck at pre-pandemic level, price rise shapes market growth

Rediff.com16 May 2023

Drug sale volumes are almost stuck at pre-pandemic levels but price growth has improved value, data from market research agency Pharmarack AWACS showed. The Indian pharmaceutical market's (IPM) volumes in April 2023 grew by 0.21 per cent when compared to April 2019. Key therapy areas like cardiac, anti-diabetic and vitamins recorded negative volume or consumption growth, while respiratory, anti-infectives, and pain and analgesics had positive growth from April 2019 to April this year.

Pharma, consumer durables sectors likely to feel China curb heat

Pharma, consumer durables sectors likely to feel China curb heat

Rediff.com12 Dec 2022

The pharmaceutical and the consumer durables sectors, which depend on China for imports, have not been impacted yet due to unrest in China with people protesting against lockdowns. But the lockdown could have an impact on the supply of components used in consumer durables if it continues for the next fortnight. In the pharmaceutical industry, Indian players import 66-70 per cent of their bulk drug requirements from China.

Rollout of new PLIs unlikely as govt eyes 'course correction'

Rollout of new PLIs unlikely as govt eyes 'course correction'

Rediff.com14 Oct 2023

The government has decided to hold off introducing the production-linked incentive (PLI) scheme for additional sectors until it verifies the efficacy of existing initiatives. Top government officials have received mixed feedback on the scheme, including insights from the Economic Advisory Council to the Prime Minister, people aware of the matter said. "There are no new PLI schemes in the offing.

Q1 a washout, exporters pin hope on North America for a turnaround

Q1 a washout, exporters pin hope on North America for a turnaround

Rediff.com3 Aug 2023

After the first quarter was washed out, exporters are now keeping their fingers crossed over a turnaround in outbound shipments to at least North America from September onwards. This comes even as other key destinations such as Europe may take longer to revive in FY24. Slowdown in key economies, as well as geopolitical tensions resulted in sluggish demand for Indian goods.

Key mantra for India's pharma sector in 2023

Key mantra for India's pharma sector in 2023

Rediff.com21 Dec 2022

Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.

Delhi detects 7 M pneumonia cases amid outbreak in China

Delhi detects 7 M pneumonia cases amid outbreak in China

Rediff.com7 Dec 2023

Mycoplasma pneumoniae has been linked to the recent surge in respiratory ailments among children in China.

AI makes mark in drug discovery in India; start-up Peptris raises $1 mn

AI makes mark in drug discovery in India; start-up Peptris raises $1 mn

Rediff.com21 Dec 2023

The process of discovering and developing a new drug can take decades and costs hundreds of millions or even billions of dollars. However, technological advances like artificial intelligence can help speed up and transform the time-consuming and labor-intensive exercise. In India, Peptris Technologies, a Bangalore-based AI drug discovery company, has announced $1 million in pre-seed round investment led by Speciale Invest.

'Follow zero tolerance': Health minister on cough syrup deaths

'Follow zero tolerance': Health minister on cough syrup deaths

Rediff.com20 Jun 2023

In an exclusive interview with PTI video, the minister also said an extensive risk-based analysis is done continuously to ensure the production of quality medicines in the country, and the government and regulators are always alert to ensure that no one dies due to spurious medicines.

Best Career Options For Science Students

Best Career Options For Science Students

Rediff.com3 Jan 2024

rediffGURU Mayank Kumar offers guidance about degree courses, campus, job-linked and executive programmes and studying abroad.

India business to put a spring in pharma's step

India business to put a spring in pharma's step

Rediff.com26 Apr 2023

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels.

Russia's Unease Over India-US Proximity

Russia's Unease Over India-US Proximity

Rediff.com5 Mar 2024

The scaling up of the India-US strategic partnership to the level of non-NATO ally with defence deals, sharing and transfer of defence technology, interoperability, joint collaboration and joint production of defence equipment has exacerbated Moscow's anxiety, notes Rup Narayan Das.

USFDA pulls up Sun Pharma for lapses in Halol plant

USFDA pulls up Sun Pharma for lapses in Halol plant

Rediff.com14 Jan 2023

The US health regulator has pulled up drug major Sun Pharma for manufacturing lapses, including failure to follow appropriate written procedures designed to prevent microbiological contamination of drug products, at its Gujarat-based plant. In a warning letter, the US Food and Drug Administration (USFDA) pointed out various lapses at the Halol plant which produces finished pharmaceutical products. "This warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," the USFDA stated.

India's Billionaire Club Has New Entrants

India's Billionaire Club Has New Entrants

Rediff.com9 Jan 2024

The IPO boom in 2023 added four new promoters to the billionaires' list.

WHO wrong in linking Gambia kids deaths to Indian cough syrups: DCGI

WHO wrong in linking Gambia kids deaths to Indian cough syrups: DCGI

Rediff.com16 Dec 2022

In the letter, Somani said the samples of four made-in-India cough syrups linked to the deaths of 66 children in Gambia which were tested in government laboratory here were found to be complying with specifications and not to have been contaminated with DEG or EG according to the test reports.

Cipla on the block: Who's a better fit and what it means for shareholders?

Cipla on the block: Who's a better fit and what it means for shareholders?

Rediff.com21 Sep 2023

India's third-largest pharmaceutical company by revenue, Cipla, is up for grabs in a three-way fight between Torrent Pharmaceuticals, Dr Reddy's Laboratories (DRL) and private equity (PE) giant Blackstone. Analysts say it is more likely for a strategic investor like Torrent or DRL to acquire Cipla than a PE firm, which may not derive healthy returns at Cipla's current market price (CMP) after the recent gains.

Walmart looking at sourcing toys, shoes, bicycles from India

Walmart looking at sourcing toys, shoes, bicycles from India

Rediff.com21 May 2023

US-based retail giant Walmart is looking to source toys, shoes and bicycles from Indian suppliers as the company is targeting to increase its exports from India to USD 10 billion annually by 2027. The company also wants to develop new suppliers in categories such as food, pharmaceuticals, consumables, health and wellness, and apparel and home textiles, a company spokesperson told PTI. Officials from the Bentonville-headquartered firm recently held a virtual meeting with several domestic toy manufacturers in India.

'Power shifts to chemists instead of doctors'

'Power shifts to chemists instead of doctors'

Rediff.com22 Aug 2023

'Whichever company offers better incentives, the chemist would prefer it.'

How Smart TV Is Changing India

How Smart TV Is Changing India

Rediff.com23 Feb 2024

The way video is being watched and monetised is changing. This is the first thing that stands out as the penetration of smart TVs continues to rise.

US sales momentum, margin gains to support pharma major Cipla's stock

US sales momentum, margin gains to support pharma major Cipla's stock

Rediff.com8 Nov 2023

A strong performance in the July-September quarter of 2023-24 (Q2FY24), an upward revision in the margin guidance and sustained momentum in US sales has helped the stock of pharmaceutical major Cipla gain about 2 per cent over the last two trading sessions. The brokerages have upgraded the earnings estimates for this financial year (FY24) by 6-9 per cent to factor in the improved margin guidance and sales in the US market. Led by the US market, which rose by 31 per cent, the company posted a 16 per cent growth in revenues.

'APIs are a very strategic part of Biocon's business'

'APIs are a very strategic part of Biocon's business'

Rediff.com7 Jan 2024

'There is no reason why we should break this business up.'

'The formulations business been a growth driver'

'The formulations business been a growth driver'

Rediff.com24 Feb 2024

'However, we have seen weakness in our active pharmaceutical ingredients business.'

Trade generics growth to dent value expansion of domestic drug market

Trade generics growth to dent value expansion of domestic drug market

Rediff.com2 Jan 2024

Rising penetration of trade generic medicines is eating into the value growth of the domestic pharmaceutical market, showed a recent analysis. According to a Kotak Institutional Equities analysis, 70-110 basis points (bps) annual dent is expected from trade generics and Jan Aushadhi on Indian Pharma Market (IPM) growth at least until FY27-28 (see chart). Trade generic medicines are those that are not pushed into the market through doctor promotions.

India's Big Guns Firing On Capex Front

India's Big Guns Firing On Capex Front

Rediff.com13 Feb 2024

'Interim Budget has ignited the entrepreneurial spirit.'

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Rediff.com14 Sep 2023

As the market buzzes with news of Cipla promoters exiting the business through a stake sale and Ahmedabad-based Mehta family-led Torrent Pharmaceuticals racing to acquire its rival, Cipla, an analysis reveals that if the deal were to go through, both companies might need to divest as many as 15 brands to comply with Competition Commission of India (CCI) norms. A recent analysis by Bernstein shows that Cipla and Torrent share a presence in 332 products (based on product and molecule data from market research firm IQVIA). Bernstein analysts Nithya Balasubramanian and Parth Shah noted that, while this may appear as a high number, a significant portion of these products lack significance.

Govt posts Manipur cadre officer as aviation secretary, rejigs bureaucracy

Govt posts Manipur cadre officer as aviation secretary, rejigs bureaucracy

Rediff.com1 Sep 2023

The Centre has appointed senior IAS officers Vumlunmang Vualnam and Neeraj Mittal as new secretaries in the ministry of civil aviation and the department of telecommunications respectively in a major secretary-level bureaucratic reshuffle, a government order stated.

Oxford-AstraZeneca Covid jab faces legal threat in UK over side effects: Report

Oxford-AstraZeneca Covid jab faces legal threat in UK over side effects: Report

Rediff.com9 Nov 2023

AstraZeneca has stressed that patient safety is its "highest priority" and pointed out that regulators around the world "consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects".

Business group linked to DMK MP among 2 raided by taxmen

Business group linked to DMK MP among 2 raided by taxmen

Rediff.com18 Oct 2023

The same day the tax sleuths had raided the house of DMK MP S Jagathrakshakan and some of those linked to him. The MP from Arakkonam has interests in a variety of business sectors.